DreaMed Diabetes on Monday said it had licensed its artificial pancreas technology for integration into insulin pumps made by Medtronic.
The Israel-based company will receive undisclosed royalties from future sales of each device using its technology. Medtronic will be responsible for the development and marketing of the pumps.
The U.S. medical device maker has also invested $2 million in DreaMed.
DreaMed’s GlucoSitter, which is based on the MD-Logic Artificial Pancreas algorithm, is an automated system for controlling glucose levels.
The material has been provided by InstaForex Company – www.instaforex.com